Effect of mutant α-synuclein on dopamine homeostasis in a new human mesencephalic cell line

被引:273
作者
Lotharius, J
Barg, S
Wiekop, P
Lundberg, C
Raymon, HK
Brundin, P
机构
[1] Lund Univ, Wallenberg Neurosci Ctr, Sect Neuronal Survival, S-22184 Lund, Sweden
[2] Lund Univ, Dept Physiol Sci, S-22184 Lund, Sweden
[3] NeuroSearch AS, Sect Microdialysis, DK-2750 Ballerup, Denmark
[4] Celgene Corp, Signal Res Div, San Diego, CA 92121 USA
关键词
D O I
10.1074/jbc.M205518200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutations in alpha-synuclein have been linked to rare, autosomal dominant forms of Parkinson's disease. Despite its ubiquitous expression, mutant alpha-synuclein primarily leads to the loss of dopamine-producing neurons in the substantia nigra. alpha-Synuclein is a presynaptic nerve terminal protein of unknown function, although several studies suggest it is important for synaptic plasticity and maintenance. The present study utilized a new human mesencephalic cell line, MESC2.10, to study the effect of A53T mutant alpha-synuclein on dopamine homeostasis. In addition to expressing markers of mature dopamine neurons, differentiated MESC2.10 cells are electrically active, produce dopamine, and express wildtype human alpha-synuclein. Lentivirus-induced overexpression of A53T mutant alpha-synuclein in differentiated MESC2.10 cells resulted in down-regulation of the vesicular dopamine transporter (VMAT2), decreased potassium-induced and increased amphetamine-induced dopamine release, enhanced cytoplasmic dopamine immunofluorescence, and increased intracellular levels of superoxide. These results suggest that mutant alpha-synuclein leads to an impairment in vesicular dopamine storage and consequent accumulation of dopamine in the cytosol, a pathogenic mechanism that underlies the toxicity of the psychostimulant amphetamine and the parkinsonian neurotoxin 1-methyl-4-phenylpyridinium. Interestingly, cells expressing A53T mutant alpha-synuclein were resistant to amphetamine-induced toxicity. Because extravesicular, cytoplasmic dopamine can be easily oxidized into reactive oxygen species and other toxic metabolites, mutations in alpha-synuelein might lead to Parkinson's disease by triggering protracted, low grade dopamine toxicity resulting in terminal degeneration and ultimately cell death.
引用
收藏
页码:38884 / 38894
页数:11
相关论文
共 90 条
[71]  
SCHMIDT CJ, 1985, J PHARMACOL EXP THER, V233, P539
[72]  
SCHULDINER S, 1993, MOL PHARMACOL, V44, P1227
[73]   CELL AND TISSUE DISTRIBUTION AND DEVELOPMENTAL-CHANGE OF NEURON-SPECIFIC 14 KDA PROTEIN (PHOSPHONEUROPROTEIN-14) [J].
SHIBAYAMAIMAZU, T ;
OKAHASHI, I ;
OMATA, K ;
NAKAJO, S ;
OCHIAI, H ;
NAKAI, Y ;
HAMA, T ;
NAKAMURA, Y ;
NAKAYA, K .
BRAIN RESEARCH, 1993, 622 (1-2) :17-25
[74]   α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies [J].
Spillantini, MG ;
Crowther, RA ;
Jakes, R ;
Hasegawa, M ;
Goedert, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (11) :6469-6473
[75]   Expression of A53T mutant but not wild-type α-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death [J].
Stefanis, L ;
Larsen, KE ;
Rideout, HJ ;
Sulzer, D ;
Greene, LA .
JOURNAL OF NEUROSCIENCE, 2001, 21 (24) :9549-9560
[76]  
SULZER D, 1995, J NEUROSCI, V15, P4102
[77]   Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity [J].
Tabrizi, SJ ;
Orth, M ;
Wilkinson, JM ;
Taanman, JW ;
Warner, TT ;
Cooper, JM ;
Schapira, AHV .
HUMAN MOLECULAR GENETICS, 2000, 9 (18) :2683-2689
[78]   Contribution of somal Lewy bodies to neuronal death [J].
Tompkins, MM ;
Hill, WD .
BRAIN RESEARCH, 1997, 775 (1-2) :24-29
[79]   Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia [J].
Trojanowski, JQ ;
Goedert, M ;
Iwatsubo, T ;
Lee, VMY .
CELL DEATH AND DIFFERENTIATION, 1998, 5 (10) :832-837
[80]   Lentiviral vectors: turning a deadly foe into a therapeutic agent [J].
Trono, D .
GENE THERAPY, 2000, 7 (01) :20-23